PYODERMA GANGRENOSUM
Clinical trials for PYODERMA GANGRENOSUM explained in plain language.
Never miss a new study
Get alerted when new PYODERMA GANGRENOSUM trials appear
Sign up with your email to follow new studies for PYODERMA GANGRENOSUM, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New wound therapy for rare skin ulcers shows early promise
Disease control TerminatedThis study tested a treatment for pyoderma gangrenosum, a rare skin condition that causes painful, hard-to-heal ulcers. Researchers used a special membrane (EpiFix) on the wounds, followed by skin grafts about a week later. The goal was to see if this approach could shrink wounds…
Matched conditions: PYODERMA GANGRENOSUM
Phase: PHASE4 • Sponsor: Louisiana State University Health Sciences Center in New Orleans • Aim: Disease control
Last updated May 17, 2026 07:53 UTC
-
Promising drug targets rare skin ulcers in early trial
Disease control TerminatedThis study tested a drug called spesolimab in 5 adults with moderate to severe pyoderma gangrenosum, a rare autoimmune disease that causes painful skin ulcers. The goal was to see if the drug could help ulcers heal by blocking a specific immune signal. The study was stopped early…
Matched conditions: PYODERMA GANGRENOSUM
Phase: PHASE2 • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Disease control
Last updated May 13, 2026 16:00 UTC
-
Promising drug trial for painful skin ulcers halted early
Disease control TerminatedThis study tested a drug called vilobelimab for people with a rare, painful skin condition that causes deep ulcers. The goal was to see if the drug could help close these wounds better than a placebo. The trial was stopped early, and results are not yet available.
Matched conditions: PYODERMA GANGRENOSUM
Phase: PHASE3 • Sponsor: InflaRx GmbH • Aim: Disease control
Last updated Apr 24, 2026 16:06 UTC